Abstract
Hypertension and the renin-angiotensin system are closely related and neither one can be described or investigated without considering the other. On a molar basis, Angiotensin II (AT) is still the most potent vasopressor agent and is therefore a prime candidate for drug induced blood pressure regulation. The octapeptide AT of the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe is produced in the circulation and not by regulated secretion like other peptide hormones, e.g. Vasopressin or ACTH (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M.B. Vallotton, The renin-angiotensin system, TIPS 8: 69 (1987).
S.A.M.A. Al-Merani, D.P. Brooks, B.J. Chapman and K.A. Munday, The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1, Ala -angiotensin II and renin in the circulatory system of the rat, J. Physiol. 278: 471 (1978).
M.I. Phillips, J. Weyhenmeyer, D. Felix, D. Ganten and W.E. Hoffman, Evidence for an endogenous brain renin-angiotensin system, Federation Proc. 38: 2260 (1979).
M.A. Ondetti, B. Rubin, D.W. Cushman, Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents, Science 196: 441 (1977).
C.S. McCaa, H.G. Langford, W.C. Cushman and R.E. McCaa, Response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of Captopril in patients with severe, treatment-resistant malignant hypertension, Clinical Science 57: 371s (1979).
M. Tree, M. Szelke, B. Leckie, B. Atrash, B. Donovan, A. Hallett, D.M. Jones, A.F. Lever, J.J. Morton, J. Sueiras-Diaz, P. Manhem, J.I.S. Robertson and D. Webb, Renin inhibitors: their use in understanding the role of angiotensin II as a pressor hormone, J. Cardiovasc. Pharmacol. 7: (Suppl.4) S49, 1985.
C. Fessier, F. Sipos, G.S. Denning, D.T. Pals and F.D. Masucci, Angiotensin II antagonism. Structure-activity relationships of 8-substituted angiotensin II analogs, J. Med. Chem. 15: 1015 (1972).
A. Aumelas, C. Sakarellos, K. Lintner, S. Fermandjian, M.C. Khosla, R.R. Smeby and F.M. Bumpus, Studies on angiotensin II and analogs: impact of substitution in position 8 on conformation and activity, Proc. Natl. Acad. Sci. 82: 1881 (1985).
F.M. Bumpus, Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor, Federation Proc. 36: 2128 (1977).
R.L. Soffer and I. Sen, Angiotensin receptor is a desirable locus for physiologically specific inhibition of the renin-angiotensin system, J. Cardiovas. Pharmacol. 7: (Suppl. 4) S69 (1985).
D. Regoli, W.K. Park and F. Rioux, Pharmacology of angiotensin, Pharmacol. Rev. 26: 69 (1974).
E.D. Frohlick, M.H. Maxwell, L. Baer, H. Gavras, J.W. Hollifield, L.R. Krakoff, M.D. Lifschitz, A. Logan, E. Poutasse, D.H.P. Streeten, A. Ochsner, Use of saralasin as a diagnostic test in hypertension, Arch. Int. Med. 142: 1437 (1982).
J. St-Louis, D. Regoli, J. Barabé and W.K. Park, Myotropic actions of angiotensin and noradrenaline in strips of rabbit aortae, Can. J. Physiol. Pharmacol. 55: 1056 (1977).
H. Glossmann, A.J. Baukal and K.J. Catt, Properties of angiotensin II receptors in the bovine and rat adrenal cortex, J. Biol. Chem. 249: 825 (1974).
G. Guillemette, G. Guillon, J. Marie, M.N. Balestre, E. Escher and S. Jard, High yield photoaffinity labeling of angiotensin II receptors, Molecular Pharmacology 30: 544 (1986).
O. Leukart, E. Escher, D. Regoli, and R. Schwyzer, Synthesis of angiotensins, bradykinins and substance P octapeptides in which the residues Phe and Tyr have been replaced with Car and of [Car, Leu]-enkephalin, Helv. Chim. Acta 62: 546 (1979).
K.Q. Do, P. Thanei, M. Caviezel and R. Schwyzer, The synthesis of (S)-(+)-2-amino-3-(1-adamantyl)-propionic acid (L-(+)-adamantylalanine, Ada) as a fat or super analogue of leucine and phenylalanine, Helv. Chim. Acta 62: 956 (1979).
E. Cuingnet, M. Dautrevaux, C. Sergheraert, A. Tartar, Synthesis and biological activity of metallocenic enkephalin analogs, Eur. J. Med. Chem. 17: 203 (1982).
J.C. Brunet, E. Cuingnet, H. Gras, P. Marcincal, A. Mocz, C. Sergheraert and A. Tartar, J. Organomet. Chem. 216: 73 (1981).
E. Escher, G. Guillemette, O. Leukard and D. Regoli, Pharmacological properties of two analogues of angiotensin II containing carboranylalanine (Car), Eur. J. Pharmacol. 66: 267 (1980).
A. Tartar, A. Demarly, C. Sergheaert, G. Frigon-Champagne and E. Escher. Metallocene angiotensin II analogues. Synthesis and biological activities, In: Peptides ′83, V. Hruby ed., Pierce Corp., Rockford, Ill. pp. 377 (1984).
E. Escher, T.M.D. Nguyen and D. Regoli, Photoaffinity labeling of the angiotensin II-receptor, Pharmacology of the labeling peptides in the dark, Can. J. Physiol. Pharmacol. 56: 956 (1978).
R. Leduc, M. Bernier and E. Escher. Angiotensin II analogues I: Syntheses and incorporation of the halogenated amino acids (4′-I)phenylalanine, (3′,5′-Br -4′-CI)phenylalanine, (3′,4′,5′-Br3)phenylalanine, and (2′,3′,4′,5′,6′-Br5)-phenylalanine, Helv. Chim. Acta 66: 960 (1983).
E. Escher, H. Mayhew, G. Guillemette, M. Bernier and D. Regoli, Tri-halogenated phenylalanine for tritium labeling of polypeptide hormones and for structure-activity studies. In Peptides, Proc. of the 6th American Peptide Symposium, E. Gross and J. Meienhofer ed., Pierce Chemical Company, Rockford, Ill. pp. 153 (1979).
J.J. Nestor, R. Tahilramani, T.L. Ho, G.I. McRae and R.H. Vickery, Luteinizing hormone-releasing hormone antagonists containing very hydrophobic amino acids, J. Med. Chem. 27: 1170, (1984).
D.N. Chaturvedi, J.J. Knittel, V.J. Hruby, A.M. de L. Castrucci and M.E. Hadley, Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins, J. Med. Chem. 27: 1406 (1984).
J. Rudinger, The design of peptide hormone analogs. In Drug Design, E.J. Ariens, ed., Acad. Press, pp. 319–419 (1971).
W. McDonald, C. Wickre, S. Aumann, D. Ban and B. Moffitt, The sustained antihypertensive effect of chronic cerebroventricular infusion of angiotensin antagonist in spontaneously hypertensive rats, Endocrinology 107: 1305 (1980).
J.F.E. Mann, E.L. Schiffrin, P.W. Schiller, W. Rascher, R. Boucher and J. Genest, Central actions and brain receptor binding of angiotensin II: Influence of sodium intake, Hypertension 2: 437 (1984).
J.E. Rivier, J. Porter, C.L. Rivier, M. Perrin, A. Corrigan, W.A. Hook, R.P. Siraganian and W.W. Vale, New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro, J. Med. Chem. 29: 1846 (1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Escher, E. (1988). Angiotensin II Antagonists with Prolonged Duration of Action Possible Anti-Hypertensive Drugs. In: Chrétien, M., McKerns, K.W. (eds) Molecular Biology of Brain and Endocrine Peptidergic Systems. Biochemical Endocrinology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8801-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8801-2_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8803-6
Online ISBN: 978-1-4684-8801-2
eBook Packages: Springer Book Archive